Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Viatris Inc. - Common Stock (NQ: VTRS )

8.999 -0.241 (-2.61%)
Streaming Delayed Price Updated: 3:54 PM EDT, Mar 13, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Viatris Inc. - Common Stock

< Previous 1 2 3 4 5 6 7 8 9
...
13 14 Next >
Q4 Earnings Highs And Lows: Amphastar Pharmaceuticals (NASDAQ:AMPH) Vs The Rest Of The Generic Pharmaceuticals Stocks
As the craze of earnings season draws to a close, here’s a look back at some of the most exciting (and some less so) results from Q4. Today, we are looking at generic pharmaceuticals stocks, starting... 
Via StockStory
Topics Artificial Intelligence Intellectual Property
Exposures Artificial Intelligence Intellectual Property
Securities Fraud Investigation Into Viatris Inc. (VTRS) Announced – Investors Who Lost Money Urged To Contact Glancy Prongay & Murray LLP, a Leading Securities Fraud Law Firm
From Glancy Prongay & Murray LLP
Via Business Wire
Viatris Inc. (VTRS) Investors Who Lost Money – Contact Law Offices of Howard G. Smith About Securities Fraud Investigation
From Law Offices of Howard G. Smith
Via Business Wire
Forecasting The Future: 4 Analyst Projections For Viatris
Via Benzinga
Earnings Scheduled For February 27, 2025
Via Benzinga
Securities Fraud Investigation Into Viatris Inc. (VTRS) Announced – Investors Who Lost Money Urged To Contact The Law Offices of Frank R. Cruz
From The Law Offices of Frank R. Cruz
Via Business Wire
1 Healthcare Stock to Target This Week and 2 to Turn Down
Personal health and wellness is one of the many secular tailwinds for healthcare companies. Despite the rosy long-term prospects, short-term headwinds such as COVID inventory destocking have harmed the... 
Via StockStory
Topics Stocks
Exposures COVID-19 US Equities
INVESTOR ALERT: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Viatris
From Faruqi & Faruqi LLP
Via GlobeNewswire
INVESTOR ALERT: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Viatris
From Faruqi & Faruqi LLP
Via GlobeNewswire
Generic Pharmaceuticals Stocks Q4 In Review: Amneal (NASDAQ:AMRX) Vs Peers
Wrapping up Q4 earnings, we look at the numbers and key takeaways for the generic pharmaceuticals stocks, including Amneal (NASDAQ:AMRX) and its peers. 
Via StockStory
Topics Artificial Intelligence Intellectual Property
Exposures Artificial Intelligence Intellectual Property
Explore the top gainers and losers within the S&P500 index in today's session.
Stay informed about the performance of the S&P500 index in the middle of the day on Monday. Uncover the top gainers and losers in today's session for valuable insights. 
Via Chartmill
Tesla, Palantir And MicroStrategy Are Among Top 12 Large-Cap Losers Last Week (Feb 24-Feb 28): Are The Others In Your Portfolio?
12 large-cap stocks plummeted last week due to negative financial reports. These include SMCI, APP, CART, NTAP, PSTG, DUOL, VTRS, SRE, PLTR, TCOM, MSTR, and TSLA. 
Via Benzinga
Stay informed with the top movers within the S&P500 index on Thursday.
Join us in exploring the top gainers and losers within the S&P500 index one hour before the close of the markets on Thursday as we examine the latest happenings in today's session. 
Via Chartmill
Why Viatris (VTRS) Shares Are Falling Today
Shares of medication company Viatris (NASDAQ:VTRS) fell 16.9% in the morning session after the company reported disappointing fourth-quarter 2024 results, with sales, earnings, and operating income all... 
Via StockStory
What's going on in today's session: S&P500 most active stocks
Stay informed about the most active S&P500 stocks in today's session as we take a closer look at what's happening on the US markets on Thursday. Discover the stocks that are generating the highest... 
Via Chartmill
Viatris Stock Tumbles On Q4 Earnings Miss, FDA Warning Clouds 2025 Outlook
Viatris missed Q4 estimates with an 8% revenue decline. 2025 guidance falls short as FDA import alert hits sales. Share repurchases prioritized. 
Via Benzinga
Topics Earnings
Exposures Financial Product Safety
Discover which S&P500 stocks are making waves on Thursday.
Let's delve into the developments on the US markets in the middle of the day on Thursday. Below, you'll find the top gainers and losers within the S&P500 index during today's session. 
Via Chartmill
Gapping S&P500 stocks in Thursday's session
Stay updated with the S&P500 gap up and gap down stocks on Thursday. Get a glimpse of the market's movement during today's session. 
Via Chartmill
Viatris Misses Estimates, Cash Flow Up
Viatris reported mixed results for Q4 2024, missing revenue and EPS expectations, despite noteworthy debt reduction and portfolio adjustments. 
Via The Motley Fool
Get insights into the top movers in the S&P500 index of Thursday's pre-market session.
Curious about the S&P500 stocks that are showing activity before the opening bell on Thursday? 
Via Chartmill
Earnings To Watch: Amneal (AMRX) Reports Q4 Results Tomorrow
Pharmaceutical company Amneal Pharmaceuticals (NASDAQ:AMRX) will be reporting results tomorrow before market hours. Here’s what investors should know. 
Via StockStory
Viatris (NASDAQ:VTRS) Misses Q4 Revenue Estimates, Stock Drops
Medication company Viatris (NASDAQ:VTRS) fell short of the market’s revenue expectations in Q4 CY2024, with sales falling 8.1% year on year to $3.53 billion. The company’s full-year revenue guidance of... 
Via StockStory
Topics Artificial Intelligence Intellectual Property
Exposures Artificial Intelligence Intellectual Property
Viatris Earnings: What To Look For From VTRS
Medication company Viatris (NASDAQ:VTRS) will be reporting results tomorrow before market open. Here’s what to expect. 
Via StockStory
Q3 Earnings Outperformers: Viatris (NASDAQ:VTRS) And The Rest Of The Generic Pharmaceuticals Stocks
The end of the earnings season is always a good time to take a step back and see who shined (and who not so much). Let’s take a look at how generic pharmaceuticals stocks fared in Q3, starting with... 
Via StockStory
Topics Artificial Intelligence Intellectual Property
Exposures Artificial Intelligence Intellectual Property
Generic Pharmaceuticals Stocks Q3 Teardown: Amneal (NASDAQ:AMRX) Vs The Rest
The end of the earnings season is always a good time to take a step back and see who shined (and who not so much). Let’s take a look at how generic pharmaceuticals stocks fared in Q3, starting with... 
Via StockStory
Topics Artificial Intelligence Intellectual Property
Exposures Artificial Intelligence Intellectual Property
3 Reasons to Sell VTRS and 1 Stock to Buy Instead
Over the past six months, Viatris’s stock price fell to $10.77. Shareholders have lost 9% of their capital, which is disappointing considering the S&P 500 has climbed by 9.3%. This might have investors... 
Via StockStory
Topics Stocks
Exposures US Equities
Unpacking Q3 Earnings: Amphastar Pharmaceuticals (NASDAQ:AMPH) In The Context Of Other Generic Pharmaceuticals Stocks
Let’s dig into the relative performance of Amphastar Pharmaceuticals (NASDAQ:AMPH) and its peers as we unravel the now-completed Q3 generic pharmaceuticals earnings season. 
Via StockStory
Topics Artificial Intelligence Intellectual Property
Exposures Artificial Intelligence Intellectual Property
ANI Pharmaceuticals (NASDAQ:ANIP): Strongest Q3 Results from the Generic Pharmaceuticals Group
Earnings results often indicate what direction a company will take in the months ahead. With Q3 behind us, let’s have a look at ANI Pharmaceuticals (NASDAQ:ANIP) and its peers. 
Via StockStory
Topics Artificial Intelligence Intellectual Property
Exposures Artificial Intelligence Intellectual Property
Current Report: Viatris Inc
Viatris Inc. is a wholly owned subsidiary of Pfizer that specializes in off-patent drugs. Share price fell about 4% in the past year from $11.88 to $11.41, as of Thursday’s market close. 
Via Talk Markets
Topics Stocks / Equities
CVS Health's Aetna Files Lawsuit Against Drugmakers For Alleged Inflated Generic Drug Prices
CVS' Aetna sues drug manufacturers for price-fixing and market allocation scheme. The subsidiary seeks damages and injunctions. 
Via Benzinga
Topics Lawsuit
Exposures Financial Legal
< Previous 1 2 3 4 5 6 7 8 9
...
13 14 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.